ストックスクリーナーアプリを入手
132.91
0.11%
0.14
Apogee Therapeutics Inc (APGE) 最新ニュース
AbbVie shares fell after six-session winning streak - MSN
Form 144 APOGEE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News - Insider Monkey
Carl Dambkowski (APGE) 10b5-1 sales total $3.5M on 06/22/2026 - Stock Titan
Avoiding Lag: Real-Time Signals in (APGE) Movement - Stock Traders Daily
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics - MSN
Apogee Therapeutics: My Take On Their Promising Eczema Drug Data Kb5089549 (eYX66guJPl) - Mshale
AbbVie (ABBV) to Acquire Apogee Therapeutics - Insider Monkey
Apogee Therapeutics Cut to Hold From Buy by Deutsche Bank - Moomoo
Apogee Therapeutics, Inc. Actuals & Estimates (NASDAQ:APGE) - TradingView
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Bill - Benzinga
AbbVie to buy Apogee Therapeutics for $10.9 billion in cash - MSN
Mizuho Securities Downgrades Apogee Therapeutics(APGE.US) to Hold Rating, Raises Target Price to $135 - Moomoo
APGE Forecast — Price Target — Prediction for 2027 - TradingView
Apogee Therapeutics CEO Henderson sells $10.6m in common stock By Investing.com - Investing.com Australia
Apogee Therapeutics Insider Sold Shares Worth $3,500,640, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Carl Dambkowski Sells 26,400 Shares of Apogee Ther - GuruFocus
Apogee Therapeutics CEO Henderson sells $10.6m in common stock - Investing.com
Form 4 Apogee Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Carl Dambkowski sells $3.5m in stock - Investing.com
Apogee Therapeutics(APGE.US) Officer Sells US$3.5 Million in Common Stock - Moomoo
Apogee Therapeutics(APGE.US) Officer Sells US$10.6 Million in Common Stock - Moomoo
Apogee Therapeutics (APGE) CEO executes 80,000-share planned stock sale - Stock Titan
Apogee Therapeutics (APGE) CMO sells 26,400 shares in planned open-market trade - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dambkowski Carl - Moomoo
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer HENDERSON MICHAEL THOMASmoomoo - Moomoo
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc.APGE - Business Wire
APGE Downgraded by Stifel -- Price Target Raised to $135 - GuruFocus
Stifel Downgrades Apogee Therapeutics(APGE.US) to Hold Rating, Announces Target Price $135 - Moomoo
Apogee Therapeutics : APGE - 24/7 Wall St.
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition By Investing.com - Investing.com South Africa
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition - Investing.com UK
BIG POTENTIAL UPSWING : APGE STOCK ANALYSIS | APOGEE THERAPEUTICS INC STOCK Alavés Vs Barcelona (ZJ4SE9HqGu) - Mshale
AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion To Rebuild Its Pipeline - Sahm
Mid-Cap Stocks Surge: Apogee Therapeutics (APGE) and Virtu Finan - GuruFocus
Form 13D/A Apogee Therapeutics For: 23 June By Investing.com - Investing.com South Africa
Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
APGE Downgraded by Citigroup -- Price Target Raised to $135 - GuruFocus
Apogee Therapeutics | SCHEDULE 13D/A: Others - Moomoo
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share - Stock Titan
APGE Downgraded by Wedbush -- Rating Adjusted to Neutral - GuruFocus
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - Benzinga
APGE Maintained by RBC Capital -- Price Target Raised to $135 - GuruFocus
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Gaining IL-13 Antibody Zumilokibart - BioPharm International
AbbVie (ABBV) Pursues Acquisition of Apogee Therapeutics - GuruFocus
American biopharmaceutical company AbbVie acquires Apogee Therapeutics for $10.9 billion - AKM.RU
Daily short sale tracking: Apogee Therapeutics's short volume increased by 7 million, with a short sale ratio of 14% - Moomoo
UBS downgrades Apogee Therapeutics stock rating on AbbVie deal By Investing.com - Investing.com India
Guggenheim Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - Yahoo Finance
Deutsche Bank Downgrades Apogee Therapeutics to Hold From Buy, Adjusts Price Target to $135 From $116 - marketscreener.com
RBC Removes 'Speculative Risk' From Apogee Therapeutics, Raises Price Target to $135 From $97 Amid AbbVie Deal, Keeps Sector Perform Rating - marketscreener.com
3.86%
大文字化:
|
ボリューム (24 時間):